Cargando…
CYT387, a JAK-Specific Inhibitor Impedes Osteoclast Activity and Oophorectomy-Induced Osteoporosis via Modulating RANKL and ROS Signaling Pathways
Osteoclasts are of hematopoietic lineage and have the ability to degrade mineralized bone tissues. Abnormalities in osteoclastic activity under certain pathological conditions are common in bone diseases such as osteoporosis, osteosclerosis, and arthritis. Although many kinds of drugs are currently...
Autores principales: | Li, Jing, Liang, Jiamin, Wu, Liwei, Xu, Yang, Xiao, Chengxiang, Yang, Xue, Sun, Ran, Zhao, Jinmin, Xu, Jiake, Liu, Qian, Zhou, Bo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957263/ https://www.ncbi.nlm.nih.gov/pubmed/35345816 http://dx.doi.org/10.3389/fphar.2022.829862 |
Ejemplares similares
-
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2013) -
CYT387, a potent IKBKE inhibitor, suppresses human glioblastoma progression by activating the Hippo pathway
por: Wang, Xin, et al.
Publicado: (2021) -
JAK1/2 Inhibitors AZD1480 and CYT387 Inhibit Canine B‐Cell Lymphoma Growth by Increasing Apoptosis and Disrupting Cell Proliferation
por: Lu, Z., et al.
Publicado: (2017) -
Inhibitory Effects of Rhaponticin on Osteoclast Formation and Resorption by Targeting RANKL-Induced NFATc1 and ROS Activity
por: He, Jianbo, et al.
Publicado: (2021) -
Berberine Sulfate Attenuates Osteoclast Differentiation through RANKL Induced NF-κB and NFAT Pathways
por: Zhou, Lin, et al.
Publicado: (2015)